Related Experiment Video
Updated: Jun 10, 2025
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.1K
Pre-emptive pharmacogenetic testing in the acute hospital setting: a cross-sectional study
John H McDermott1,2, Kerry Burke2,3, Neil Fullerton1
1Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Oxford Road, Manchester, UK.
QJM : Monthly Journal of the Association of Physicians
|October 17, 2024
Summary
Panel-based pharmacogenetic testing in acutely admitted patients reveals high utility. Nearly 14% experienced actionable gene-drug interactions, with older age increasing risk, underscoring the need for integrated testing infrastructure.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Pharmacogenetic-guided prescribing enhances medication safety and effectiveness.
- Implementation strategies vary based on healthcare systems and clinical settings.
Purpose of the Study:
- Assess the clinical utility of panel-based pharmacogenetic testing in acutely hospitalized patients.
- Identify predictors for benefiting from pharmacogenetic testing.
Main Methods:
- Cross-sectional study of acutely hospitalized patients.
- Panel-based pharmacogenetic testing and analysis of gene-drug interactions based on inpatient medication exposure.
- Logistic regression used to identify predictive variables for clinical utility.
Main Results:
- 482 inpatients (median age 61.2 years) were analyzed; 97.9% had relevant pharmacogenetic results.
- 79.5% of patients received medications with available pharmacogenetic guidance.
- 13.7% had clinically actionable gene-drug interactions; age >50 increased risk 2.7-fold.
Conclusions:
- Pharmacogenetic testing shows significant potential and clinical utility in acute hospital settings.
- Infrastructure development is crucial to support healthcare professionals in utilizing pharmacogenetic testing.
- Testing can identify actionable gene-drug interactions, particularly in older patients.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
237
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
237
01:19Pharmacovigilance
783
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
783